Shire settles with Impax on Adderall XR authorized generic; initiates Ph III ABH001 study
10 February 2013
Another stumbling block for Impax Pharma's Rytary
22 January 2013
Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion
21 December 2012
Impax in deal with Perrigo; Cipla eyes South Africa acquisition
22 November 2012
Teva/Impax generic Wellbutrin XL 300mg pulled from US market on non-bioequivalence grounds
4 October 2012
Impax Labs and Teva settle Concerta litigation with J&J units
17 September 2012
Impax Labs settles with Genzyme over Renvela and Renagel generics
5 September 2012
Impax buys US rights to Zomig
1 February 2012
Perrigo confirms ANDA filing for generic Astepro nasal spray
24 January 2012
Impax confirms patent challenge to GlaxoSmithKline’s Jalyn; Albemarle hikes API prices
14 September 2011
Exec appointments at SkyePharma, Impax, Ariad and Regeneron
7 September 2011
Positive top-line Ph III results of Impax and GSK IPX066 in advanced Parkinson’s disease
16 August 2011
Shire files suit against Impax and Watson over Intuniv patent
6 December 2010
Impax Labs sued by Johnson & Johnson unit over Concerta patent
1 December 2010
Abbott Labs files suit against Impax over Simcor patent challenge; Ranbaxy debuts generic Aricept in USA
29 November 2010
Merck & Co sues Impax Labs over Vytorin patent infringement in USA, as firm faces “patent cliff”
24 August 2010
Forest/Merz settle with Mylan and others of generic Namenda; Impax’ generic Opana cleared in USA
23 July 2010
Impax now to co-promote Pfizer’s Lyrica; updates on APEX-PD trial; Pfizer in deal with Stemgent on reagents
16 April 2010
Showing 1-29 of 29 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
